Background Tranexamic acid (TXA), an antifibrinolytic agent, is a synthetic lysine analog that inhibits fibrinolysis and improves clot stability. When administered to medical, elective, and emergency surgical patients, TXA can reduce bleeding and transfusion requirements, thereby reducing mortality in such cases. Recommended use The World Health Organization (WHO) recommends intravenous TXA within three hours postpartum in addition to standard care for cases of clinically diagnosed postpartum hemorrhage (PPH).
TXA must be administered at a fixed dose of 1 g in 10 ml (100 mg/ml) IV at 1 ml per minute, with a second dose of 1g/10ml IV if bleeding persists beyond 30 minutes. Associated risks Owing to its role in managing critical PPH from a vaginal birth or cesarean section, TXA is often stored near other essential and similar-looking drugs (transparent ampoule containing transparent…
